Latest Insider Transactions at Sensei Biotherapeutics, Inc. (SNSE)
This section provides a real-time view of insider transactions for Sensei Biotherapeutics, Inc. (SNSE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Sensei Biotherapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Sensei Biotherapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 15
2024
|
Horst Edward Van Der CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,843
-4.83%
|
$0
$0.79 P/Share
|
|
Feb 15
2024
|
Erin Colgan CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,627
-5.1%
|
$0
$0.79 P/Share
|
|
Feb 15
2024
|
John Celebi PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,891
-5.29%
|
$0
$0.79 P/Share
|
|
Sep 11
2023
|
John Celebi PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
500
+0.45%
|
$0
$0.85 P/Share
|
|
Jul 31
2023
|
Cambrian Bio Pharma Inc |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,587,302
-30.29%
|
$1,587,302
$1.26 P/Share
|
|
Jul 31
2023
|
James Peyer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,587,302
-30.29%
|
$1,587,302
$1.26 P/Share
|
|
Jul 10
2023
|
Samuel Broder Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+33.33%
|
-
|
|
Jul 10
2023
|
Thomas G Ricks |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+33.33%
|
-
|
|
Jul 10
2023
|
William R Ringo |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+16.03%
|
-
|
|
Jul 10
2023
|
Kristian Humer |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+33.33%
|
-
|
|
Jul 10
2023
|
Deneen Vojta |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+33.33%
|
-
|
|
Jul 10
2023
|
Jessie English |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+33.33%
|
-
|
|
Jul 10
2023
|
Bob Holmen |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+14.86%
|
-
|
|
Jul 10
2023
|
Cambrian Bio Pharma Inc |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+0.09%
|
-
|
|
Jul 10
2023
|
James Peyer |
BUY
Grant, award, or other acquisition
|
Indirect |
4,466
+0.09%
|
-
|
|
Jun 01
2023
|
Apeiron Investment Group Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,441,661
-100.0%
|
$3,441,661
$1.58 P/Share
|
|
Feb 23
2023
|
Apeiron Investment Group Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,200
+0.04%
|
$2,200
$1.61 P/Share
|
|
Feb 15
2023
|
Patrick Stephen Gallagher Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,383
-21.56%
|
$9,383
$1.5 P/Share
|
|
Feb 15
2023
|
Erin Colgan CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
10,943
-13.85%
|
$10,943
$1.5 P/Share
|
|
Feb 15
2023
|
John Celebi PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
20,492
-15.61%
|
$20,492
$1.5 P/Share
|
|
Feb 15
2023
|
Horst Edward Van Der CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
9,525
-15.26%
|
$9,525
$1.5 P/Share
|
|
Feb 15
2023
|
John Celebi PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
73,193
+23.6%
|
-
|
|
Feb 15
2023
|
Erin Colgan CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
51,346
+29.66%
|
-
|
|
Feb 15
2023
|
Patrick Stephen Gallagher Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,513
+37.3%
|
-
|
|
Feb 15
2023
|
Horst Edward Van Der CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
41,265
+28.29%
|
-
|
|
Jun 10
2022
|
Bob Holmen |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+17.45%
|
-
|
|
Jun 10
2022
|
Samuel Broder Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+50.0%
|
-
|
|
Jun 10
2022
|
Kristian Humer |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+50.0%
|
-
|
|
Jun 10
2022
|
Thomas G Ricks |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+50.0%
|
-
|
|
Jun 10
2022
|
Jessie English |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+50.0%
|
-
|
|
Jun 10
2022
|
Deneen Vojta |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+50.0%
|
-
|
|
Jun 10
2022
|
James Peyer |
BUY
Grant, award, or other acquisition
|
Indirect |
4,466
+0.09%
|
-
|
|
Jun 10
2022
|
Cambrian Bio Pharma Inc |
BUY
Grant, award, or other acquisition
|
Direct |
4,466
+0.09%
|
-
|
|
Mar 08
2022
|
William R Ringo |
BUY
Grant, award, or other acquisition
|
Direct |
18,933
+42.28%
|
-
|
|
Mar 02
2022
|
James Peyer |
BUY
Open market or private purchase
|
Indirect |
1,203
+0.02%
|
$3,609
$3.2 P/Share
|
|
Mar 02
2022
|
Cambrian Bio Pharma Inc |
BUY
Open market or private purchase
|
Direct |
1,203
+0.02%
|
$3,609
$3.2 P/Share
|
|
Mar 01
2022
|
Cambrian Bio Pharma Inc |
BUY
Open market or private purchase
|
Direct |
2,458
+0.05%
|
$7,374
$3.6 P/Share
|
|
Mar 01
2022
|
James Peyer |
BUY
Open market or private purchase
|
Indirect |
2,458
+0.05%
|
$7,374
$3.6 P/Share
|
|
Feb 28
2022
|
Cambrian Bio Pharma Inc |
BUY
Open market or private purchase
|
Direct |
42
+0.0%
|
$126
$3.6 P/Share
|
|
Feb 28
2022
|
James Peyer |
BUY
Open market or private purchase
|
Indirect |
42
+0.0%
|
$126
$3.6 P/Share
|
|
Feb 25
2022
|
Cambrian Bio Pharma Inc |
BUY
Open market or private purchase
|
Direct |
2,500
+0.05%
|
$7,500
$3.65 P/Share
|
|
Feb 25
2022
|
James Peyer |
BUY
Open market or private purchase
|
Indirect |
2,500
+0.05%
|
$7,500
$3.65 P/Share
|
|
Feb 24
2022
|
James Peyer |
BUY
Open market or private purchase
|
Indirect |
15,000
+0.29%
|
$45,000
$3.63 P/Share
|
|
Feb 24
2022
|
Cambrian Bio Pharma Inc |
BUY
Open market or private purchase
|
Direct |
15,000
+0.29%
|
$45,000
$3.63 P/Share
|
|
Feb 23
2022
|
James Peyer |
BUY
Open market or private purchase
|
Indirect |
2,500
+0.05%
|
$7,500
$3.8 P/Share
|
|
Feb 23
2022
|
Cambrian Bio Pharma Inc |
BUY
Open market or private purchase
|
Direct |
2,500
+0.05%
|
$7,500
$3.8 P/Share
|
|
Feb 18
2022
|
Cambrian Bio Pharma Inc |
BUY
Open market or private purchase
|
Direct |
15,000
+0.29%
|
$45,000
$3.97 P/Share
|
|
Feb 18
2022
|
James Peyer |
BUY
Open market or private purchase
|
Indirect |
15,000
+0.29%
|
$45,000
$3.97 P/Share
|
|
Feb 17
2022
|
Cambrian Bio Pharma Inc |
BUY
Open market or private purchase
|
Direct |
4,949
+0.1%
|
$19,796
$4.17 P/Share
|
|
Feb 17
2022
|
James Peyer |
BUY
Open market or private purchase
|
Indirect |
4,949
+0.1%
|
$19,796
$4.17 P/Share
|